Wedbush raised the firm’s price target on Immunome (IMNM) to $19 from $12 and keeps an Outperform rating on the shares. The firm cites the company’s recent acquisition of IM-1021 from Zentalis (ZNTL). IM-1021 is a ROR1-targeted ADC that is on track for an IND submission in Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMNM:
- Immunome, Zentalis enter exclusive, worldwide ZPC-21 license agreement
- Immunome appoints Phil Roberts as Chief Technical Officer
- Biotech Alert: Searches spiking for these stocks today
- Immunome to acquire antibody-related assets, materials from Atreca
- Atreca announces asset purchase agreement for sale of assets to Immunome
